Tau and amyloid beta (Aβ) are the prime suspects for driving pathology in Alzheimer's
disease (AD) and, as such, have become the focus of therapeutic development. Recent …

Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The
presence of extracellular β-amyloid deposition as neuritic plaques and intracellular …

Animal models of human diseases that accurately recapitulate clinical pathology are
indispensable for understanding molecular mechanisms and advancing preclinical studies …

Alzheimer's disease (AD) is characterized by amyloid beta (Aβ) accumulation, tau pathology
and neuroinflammation. Recently, there has been considerable interest in the role of …

Alzheimer disease (AD) is the most common cause of dementia in older individuals (> 65
years) and has a long presymptomatic phase. Preventive therapies for AD are not yet …

Since its discovery in 1984, the beta amyloid peptide has treaded the boards of
neurosciences as the star molecule in Alzheimer's disease pathogenesis. In the last decade …

Alzheimer's disease (AD) is marked by the presence of extracellular amyloid beta (Aβ)
plaques, intracellular neurofibrillary tangles (NFTs) and gliosis, activated glial cells, in the …

The β secretase, widely known as β-site amyloid precursor protein cleaving enzyme 1
(BACE1), initiates the production of the toxic amyloid β (Aβ) that plays a crucial early part in …

To realize the therapeutic potential of RNA drugs, efficient, tissue-specific and
nonimmunogenic delivery technologies must be developed. Here we show that exosomes …

Cathepsin B (CTSB) is a powerful lysosomal protease. This review evaluated CTSB gene
knockout (KO) outcomes for amelioration of brain dysfunctions in neurologic diseases and …